Jefferies is out with its report today on Dynavax Technologies DVAX, maintaining Buy.
In a note to clients, Jefferies writes, "We continue to believe Heplisav may become the preferred HBV vaccine for poor responders to current vaccines and to see diabetes as a major new opportunity not captured in the current valuation. We expect Heplisav approval in late 2012/early 2013, with a potential vote on the diabetes mandate as early as October. At our healthcare conference, DVAX management provided several positive clinical and regulatory updates on Heplisav."
Jefferies maintains a $4.00 PT on DVAX.
Shares of DVAX closed Wednesday at $2.51, down 0.40% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in